Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.

Abstract

BACKGROUND Epoetin-zeta (epoetin-ζ) (sold as Retacrit™/Silapo™) is a biologic product that was approved by the European Medicines Agency in 2007 after demonstrating biosimilarity to its reference product epoetin-α (Eprex™), based on a comprehensive comparability exercise including extensive biophysical characterization and three double-blind randomized… (More)
DOI: 10.5414/CN108484

Topics

  • Presentations referencing similar topics